KLF10 Polypeptide Induces T Regulatory Phenotype for Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases such as type I diabetes, multiple sclerosis, inflammatory bowel disease, and atherosclerosis are limited, necessitating new strategies for modulating T regulatory cell function to combat these chronic inflammatory conditions.
Innovation Solution
The use of KLF10, which is expressed in T regulatory cells, to induce a T regulatory phenotype by administering a KLF10 polypeptide or fragment, either systemically or locally, to promote the function and number of CD4+CD25+ T regulatory cells, thereby suppressing inflammation and limiting disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for autoimmune diseases are used, then existing therapeutic options are maintained, but treatment effectiveness is limited and new strategies are needed
Solution Approach 1:
The patent changes the therapeutic parameter from conventional treatments to KLF10 polypeptide administration, which specifically modulates T regulatory cell function. This parameter change enables both improved treatment effectiveness through targeted immunomodulation and increased versatility by providing a novel therapeutic mechanism distinct from existing treatments for autoimmune diseases
Solution Approach 2:
KLF10 polypeptide serves as an intermediary substance that mediates the therapeutic effect by inducing T regulatory phenotype and enhancing suppression function. This intermediary approach resolves the contradiction by providing a specific molecular mechanism that improves treatment effectiveness while offering a new therapeutic strategy beyond current limited options
2Reliability
If T regulatory cell function is enhanced through KLF10 administration, then inflammation suppression is improved, but the complexity of the therapeutic mechanism increases
Solution Approach 1:
The patent extracts and isolates the specific function of KLF10 in inducing T regulatory phenotype, separating this beneficial mechanism from the complexity of the entire immune system. By focusing on this single extracted function, the patent achieves reliable inflammation suppression through a defined mechanism rather than attempting to modulate the entire immune response
Solution Approach 2:
The therapeutic mechanism is segmented into distinct functional components: KLF10 administration, T regulatory phenotype induction, and suppression function enhancement. This segmentation allows each component to be studied and optimized independently, reducing the overall complexity while maintaining reliable inflammation suppression
Data Source
AI summary
The present invention provides methods and compositions for treating chronic inflammatory disease in a subject and associated pharmaceutical compositions, medical devices and systems.